Zenas BioPharma (NASDAQ:ZBIO) Receives “Buy” Rating from HC Wainwright

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $44.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 89.41% from the stock’s previous close.

A number of other equities analysts have also commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Morgan Stanley lifted their target price on shares of Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a report on Tuesday. Wall Street Zen raised shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Jefferies Financial Group restated a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a report on Tuesday, January 6th. Finally, Wedbush reiterated an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research note on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.17.

Zenas BioPharma Trading Down 3.4%

Zenas BioPharma stock opened at $23.23 on Tuesday. Zenas BioPharma has a one year low of $6.11 and a one year high of $44.60. The company’s fifty day moving average price is $22.61 and its two-hundred day moving average price is $27.12. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -3.29 and a beta of -1.96.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Monday, March 16th. The company reported ($4.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Insider Activity at Zenas BioPharma

In other news, Director Hongbo Lu acquired 25,985 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The shares were bought at an average price of $22.50 per share, with a total value of $584,662.50. Following the acquisition, the director owned 347,968 shares of the company’s stock, valued at $7,829,280. This trade represents a 8.07% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Leon O. Moulder, Jr. bought 57,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was purchased at an average price of $17.96 per share, with a total value of $1,023,720.00. Following the completion of the purchase, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at $7,599,863.80. This represents a 15.57% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 202,845 shares of company stock worth $3,747,185 over the last three months. Company insiders own 16.50% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

A number of institutional investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. raised its stake in shares of Zenas BioPharma by 41.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after buying an additional 2,679 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after acquiring an additional 16,461 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of Zenas BioPharma by 13.9% during the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock valued at $128,000 after acquiring an additional 1,607 shares in the last quarter. Rhumbline Advisers increased its stake in Zenas BioPharma by 71.3% in the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after acquiring an additional 8,207 shares during the period. Finally, Federated Hermes Inc. raised its position in Zenas BioPharma by 60.8% in the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after purchasing an additional 703,838 shares in the last quarter.

Key Headlines Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company secured up to $250 million in non-dilutive, multi‑tranche debt financing from Pharmakon to support development and commercialization plans—improves near-term liquidity and reduces immediate dilution risk. Zenas BioPharma Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Regulatory milestones: Zenas expects to file obexelimab marketing applications for IgG4‑RD with the FDA in Q2 2026 and with the EMA in H2 2026; SunStone SLE topline is due Q4 2026 — these near‑term milestones can materially re‑rate the stock if positive. Zenas BioPharma Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Insider and institutional buying highlighted in recent data (multiple insiders and funds increased stakes), which can signal confidence from management and large holders. Quiver Quant — Inducement Grants (also shows insider activity)
• Neutral Sentiment: Morgan Stanley analyst Judah Frommer maintained a Hold and raised the price target to $21 — the raise is supportive, but the PT remains below some prior analyst targets and near current trading levels, signaling mixed analyst sentiment. TipRanks — Morgan Stanley Rating
• Neutral Sentiment: Company granted inducement stock options (235,700 options at $23.23 and 33,450 RSUs) to new hires to aid recruitment; standard for growth-stage biotech but adds potential future dilution as awards vest. GlobeNewswire — Inducement Grants
• Negative Sentiment: Quarterly GAAP EPS missed heavily: Zenas reported a loss of $4.54 per share vs. consensus roughly -$1.22 — the magnitude of the miss drove investor concern about execution and near‑term profitability. Quarterly Earnings Press Release
• Negative Sentiment: New disclosure of an IPO‑related securities class action expands legal risk and potential financial/operational uncertainty for the company. TipRanks — IPO-Related Securities Class Action

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.